NCT01105741View on ClinicalTrials.gov

Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

December 31, 2013

Conditions
Crohn's Disease
Trial Locations (1)

T2N 4N1

Division of Gastroenterology, Calgary

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Martin Storr

OTHER

NCT01105741 - Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD) | Biotech Hunter | Biotech Hunter